Patient P-02168
Synthetic patientMETA-24 · Day 176 · 65–74 · F · baseline S15Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
65%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S15
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −23% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 80 GI symptom burden −27% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
- Day 88 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 89 ME-01 recommended — Monitoring Escalation ME-01
- Day 90 Patient accepted — Started ME-01 in the companion
- Day 93 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 88.
Primary contributors, last 14 days
- GI instability+8
- Toxicity-5
- Treatment adherence+4
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −23%
- GI Support Protocol GI-04Day 71Result: symptom burden −27%
- Monitoring Escalation ME-01Day 89Result: deterioration detected before clinical escalation
LIFE OS recommendation
Clinician Review CR-01
74%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable53 min
worsening · -8.5 vs previous 14 d
Sleep duration
Wearable6 h
stable · -0.0 vs previous 14 d
Energy level
Daily log3.1/10
worsening · -0.7 vs previous 14 d
Steps
Wearable6,003
stable · -192 vs previous 14 d
GI burden
Companion58.3/100
worsening · +5.0 vs previous 14 d
Adherence
Companion52.4 %
stable · +0.8 vs previous 14 d
Sleep quality
Wearable26.2/100
worsening · -0.8 vs previous 14 d
Glucose, CGM daily mean
CGM140 mg/dL
stable · -2.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 29 from the failing basin, 61 from restoration.
Would help
Would not help
- Keep fat lowGI +4.9 next day on high-intake days · n 22
- Keep alcohol lowGI +4 next day on high-intake days · n 20
- Keep simple carbs lowGI +3.6 next day on high-intake days · n 20
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+4.9detractor · 95%
- Protein-4.4supporter · 95%
- Alcohol+4detractor · 95%
- Simple carbohydrates+3.6detractor · 91%
- Ultra-processed food+3.3detractor · 88%
- Histamine load+3.1detractor · 86%
- Caffeine-1.5no signal · 34%
- Insoluble fibre+1.2no signal · 27%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 58 and rising
- WearableSleep 6.0 h, below personal baseline
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
- WearableHRV 33 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 78 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 2.1 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 31 ms
- Sleep
- 5.7 h
- Steps
- 6,103
- Resting HR
- 78 bpm
Daily log: GI score 58, nutritional resilience 45, adherence 52.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02552 | 23% | S07 | AD-05 | no change | 29 |
| P-02093 | 22% | S05 | AD-05 | no change | 40 |
| P-02483 | 24% | S06 | BR-03 | no change | 64 |
| P-02087 | 22% | S01 | BR-03 | no change | 40 |
| P-02308 | 22% | S13 | BR-03 | no change | 27 |
| P-02054 | 34% | S01 | CR-01 | improved | 57 |
| P-02151 | 34% | S04 | CR-01 | improved | 49 |
| P-02025 | 32% | S15 | CR-01 | improved | 61 |
| P-02009 | 31% | S08 | CR-01 | improved | 64 |
| P-02154 | 30% | S16 | CR-01 | improved | 57 |
| P-02233 | 30% | S16 | CR-01 | improved | 66 |
| P-02395 | 24% | S12 | DT-01 | improved | 57 |